Skip to main content
Veterinary Medicines

FELIDIARIX 50,0 MG / 8 375 UI / 0,0021 MG COMPRIMES PELLICULES POUR CHATS

Authorised
  • Framycetin sulfate
  • Atropine sulfate monohydrate
  • Sulfaguanidine

Product identification

Medicine name:
FELIDIARIX 50,0 MG / 8 375 UI / 0,0021 MG COMPRIMES PELLICULES POUR CHATS
Active substance:
  • Framycetin sulfate
  • Atropine sulfate monohydrate
  • Sulfaguanidine
Target species:
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Framycetin sulfate
    8375.00
    international unit(s)
    /
    1.00
    Tablet
  • Atropine sulfate monohydrate
    0.00
    milligram(s)
    /
    1.00
    Tablet
  • Sulfaguanidine
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Withdrawal period by route of administration:
  • Oral use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QA07AA99
Authorisation status:
  • Valid
Authorised in:
  • France
Available in:
  • France
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Domes Pharma
Marketing authorisation date:
Manufacturing sites for batch release:
  • EUROPHARTECH
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/4241651 1/1989
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 26/03/2024

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 26/03/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."